Sernova, AstraZeneca to Collaborate to Evaluate Potential Therapeutic Cell Applications

By Robb M. Stewart

Biotechnology company Sernova said Wednesday it entered a preclinical research collaboration with AstraZeneca to evaluate the use of its Cell Pouch System in combination with AstraZeneca's novel therapeutic cells.

The company said AstraZeneca is exploring the use of the Cell Pouch System as a potential platform for integration with its development of the next wave of cell therapies for various indications.

Under the terms of the collaboration, AstraZeneca would lead and completely fund the development of the cell technologies and preclinical activities in conjunction with Sernova. The discovery work is being funded and conducted at AstraZeneca, Sernova said.

The preclinical research outcomes would determine the feasibility of potential therapeutic applications and subsequent product development activities between the two companies, it said.

Sernova said it has developed a cell therapy approach for the potential treatment of insulin-dependent diabetes, hypothyroidism and hemophilia A.

Write to Robb M. Stewart at robb.stewart@wsj.com

(END) Dow Jones Newswires

May 03, 2023 07:38 ET (11:38 GMT)

Sernova (TSX:SVA)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024